PMID- 16315783
OWN - NLM
STAT- MEDLINE
DCOM- 20060126
LR  - 20161021
IS  - 1124-0490 (Print)
IS  - 1124-0490 (Linking)
VI  - 22
IP  - 3
DP  - 2005 Oct
TI  - Investigation of IL-18 and IL-12 in induced sputum of patients with IPF before 
      and after treatment with interferon gamma-1b.
PG  - 204-9
AB  - BACKGROUND AND AIM: Interleukin-18 (IL-18) has been identified as an 
      interferon-gamma (IFN-gamma) mediator, promoting a T helper 1 (Th1) response. Th1 
      response is characterized by increased expression of IFN-gamma, interleukin-12 
      (IL-12) and interleukin-18 (IL-18). The present study aims to evaluate the role 
      of Th1 cytokines by monitoring changes in Induced Sputum (IS) samples, before and 
      after treatment with IFN-gamma-1b in patients with IPF. PATIENTS AND METHODS: 
      Fifteen patients with histologically confirmed IPF/UIP (12 male, 3 female) of 
      median age 65 yr were prospectively studied. Ten healthy subjects (5 female, 5 
      male) of median age 61 yr served as control group. Patients were assigned to 
      receive IFN-gamma-1b 200 microg (15 patients) subcutaneously three times per week 
      for 12 months. Induced sputum (IS) IL-12 and IL-18 levels were measured before 
      and after IFN-gamma-1b treatment in IPF patients as well as in healthy controls, 
      using ELISA immunoassay. RESULTS: The IL-18 levels were significantly higher in 
      IPF samples before treatment than in healthy controls (57.05 +/- 6.9 pg/ml vs. 
      41.07 +/- 8.16 pg/ml, p < 0.05). A statistically significant decrease was 
      detected in the IL-18 levels after IFN-gamma-1b treatment (57.05 +/- 6.9 vs. 42.8 
      +/- 5.1 pg/ml, p = 0.04). The IL-12 supernatant levels measured before and after 
      IFN-gamma-1b treatment were not significantly different. CONCLUSIONS: Our results 
      may illustrate the potential role of IL-18 as an inflammatory molecule in the 
      pathogenesis of IPF. Moreover, decrease of IL-18 levels in IPF patients, after 12 
      months of therapy could possibly be explained as IL-18 downregulation after 
      IFN-gamma-1b treatment. Extended studies are needed to determine the precise role 
      of IL-12 and IL-18 during IPF.
FAU - Antoniou, Katerina M
AU  - Antoniou KM
AD  - Interstitial Lung Disease Unit, Department of Thoracic Medicine, University 
      General Hospital, Medical School, University of Crete, Heraklion.
FAU - Tzortzaki, Eleni G
AU  - Tzortzaki EG
FAU - Alexandrakis, Michael G
AU  - Alexandrakis MG
FAU - Zervou, Maria
AU  - Zervou M
FAU - Tzanakis, Nikolaos
AU  - Tzanakis N
FAU - Sfiridaki, Katerina
AU  - Sfiridaki K
FAU - Bouros, Demosthenes E
AU  - Bouros DE
FAU - Siafakas, Nikolaos M
AU  - Siafakas NM
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Italy
TA  - Sarcoidosis Vasc Diffuse Lung Dis
JT  - Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG
JID - 9610928
RN  - 0 (Antiviral Agents)
RN  - 0 (Interleukin-18)
RN  - 0 (Recombinant Proteins)
RN  - 142M471B3J (Carbon Dioxide)
RN  - 187348-17-0 (Interleukin-12)
RN  - 82115-62-6 (Interferon-gamma)
RN  - S88TT14065 (Oxygen)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antiviral Agents/therapeutic use
MH  - Carbon Dioxide/blood
MH  - Female
MH  - Humans
MH  - Interferon-gamma/*therapeutic use
MH  - Interleukin-12/*analysis
MH  - Interleukin-18/*analysis
MH  - Male
MH  - Middle Aged
MH  - Oxygen/blood
MH  - Pulmonary Fibrosis/*drug therapy/*immunology/physiopathology
MH  - Recombinant Proteins
MH  - Reference Values
MH  - Respiratory Function Tests
MH  - Sputum/*immunology
EDAT- 2005/12/01 09:00
MHDA- 2006/01/27 09:00
CRDT- 2005/12/01 09:00
PHST- 2005/12/01 09:00 [pubmed]
PHST- 2006/01/27 09:00 [medline]
PHST- 2005/12/01 09:00 [entrez]
PST - ppublish
SO  - Sarcoidosis Vasc Diffuse Lung Dis. 2005 Oct;22(3):204-9.